make
select
cellular
tool
anim
model
gener
screen
assay
search
new
drug
one
need
take
consider
practic
use
drug
discoveri
process
conduct
highthroughput
primari
screen
use
librari
small
molecul
close
million
member
size
requir
gener
larg
number
cell
easili
acquir
reliabl
enrich
reproduc
respons
standard
posit
control
cell
need
similar
form
function
counterpart
human
diseas
vitro
assay
mechan
use
robot
therefor
save
time
cost
select
vivo
model
consider
must
given
speci
strain
anim
chosen
appropri
model
human
diseas
extent
anim
husbandri
requir
inlif
pharmacolog
assess
technic
aspect
gener
model
harvest
tissu
analys
cost
research
tool
term
time
money
demyelin
remyelin
agent
amount
compound
gener
length
time
requir
drug
test
model
consider
translat
aspect
vivo
model
compar
use
clinic
also
import
theme
develop
exampl
drug
discoveri
field
cn
demyelin
repair
specif
pertain
multipl
sclerosi
multipl
sclerosi
ms
autoimmun
diseas
human
whose
key
patholog
demyelin
axon
loss
result
immun
cell
product
proinflammatori
molecul
activ
attack
myelin
sheath
cell
produc
oligodendrocyt
hallmark
patholog
plaqu
found
myelinrich
white
matter
region
central
nervou
system
cn
brain
spinal
cord
destruct
myelin
oligodendrocyt
ultim
axon
mediat
activ
cell
autoantibodi
direct
selfantigen
enzym
free
radic
secret
macrophag
microglia
prinea
et
al
rain
wu
oligodendrocyt
progenitor
resid
throughout
cn
birth
well
old
age
human
brain
roy
et
al
nune
et
al
well
document
cell
activ
cn
patholog
ms
migrat
lesion
site
attempt
repair
damag
differenti
remyelin
nake
axon
prinea
connel
prinea
et
al
prinea
et
al
prinea
et
al
rain
wu
lassmann
et
al
continuum
myelin
breakdown
repair
seen
major
lesion
ms
tissu
led
explor
process
repair
cn
use
basic
model
demyelin
remyelin
vitro
model
event
anim
understand
remyelin
recapitul
process
known
occur
primari
myelin
grow
knowledg
local
environment
factor
caus
demyelin
preventpromot
remyelin
recognit
use
small
molecul
biolog
pharmacolog
intervent
might
har
endogen
repair
process
treat
ms
explor
chapter
sim
et
al
sim
et
al
franklin
blakemor
blakemor
franklin
specif
focu
tool
lend
drug
discoveri
process
bridg
gap
model
man
address
larg
area
research
use
experiment
model
cover
entireti
chapter
intend
thorough
review
literatur
initi
descript
contemporari
paper
model
vitro
vivo
demyelin
remyelin
review
everi
dose
regimen
explor
everi
variat
diseas
induct
paradigm
model
argu
fine
point
except
patholog
elicit
given
model
mani
case
especi
current
gener
use
model
deviat
major
way
origin
descript
origin
refer
cite
chapter
also
intend
go
beyond
preclin
efficaci
studi
use
model
purpos
therefor
issu
surround
clinic
trial
ideal
drug
candid
outsid
realm
chapter
neither
pro
con
therapeut
modal
model
man
safeti
studi
vivo
model
intend
part
discuss
use
model
evalu
effect
drug
nevertheless
exampl
drug
current
clinic
trial
use
model
discuss
respect
hurdl
assess
remyelin
clinic
primari
rodent
cultur
system
lend
evalu
oligodendrocyt
differ
stage
differenti
within
commit
lineag
mccarthi
develli
prolif
migratori
bipolar
oligodendrocyt
precursor
rat
identifi
monoclon
antibodi
gangliosid
cell
also
posit
plateletderiv
growth
factora
receptor
pdgfar
express
among
other
transcript
factor
pou
iii
sox
krox
pfeiffer
et
al
nicolay
et
al
prooligodendrocyt
multipolar
postmigratori
prolif
cell
identifi
antibodi
sulfat
surfac
antigen
poa
sox
mash
transcript
factor
seen
stage
premyelin
oligodendrocyt
express
galactocerebrosid
galc
sulfatid
cyclic
nucleotid
phosphohydrolas
cnp
detect
antigalc
antisulfatid
anticnp
antibodi
respect
cell
stage
express
complex
branch
secondari
tertiari
process
matur
myelinproduc
oligodendrocyt
identifi
antibodi
myelin
basic
protein
mbp
proteolipid
protein
plp
myelin
oligodendrocyt
glycoprotein
mog
complex
myelin
sheath
readili
seen
transcript
factor
detect
stage
revers
transcriptas
rt
pcr
microfluid
card
use
identifi
mrna
signatur
receptor
myelin
gene
transcript
factor
antibodi
astrocyt
antigli
fibrillari
acid
protein
gfap
microglia
rat
mous
typic
use
cultur
detect
potenti
contamin
cell
type
human
fetal
oligodendrocyt
precursor
obtain
postmortem
human
fetal
spinal
cord
brain
week
gestat
enrich
achiev
separ
immunomagnet
microbead
coat
rat
antimous
igm
captur
progenitor
label
antibodi
separ
differenti
adher
properti
follow
growth
oligodendrocyteenhanc
medium
day
plate
polyllysineco
plate
yield
approxim
enrich
cell
miron
et
al
miron
et
al
wilson
et
al
zhang
et
al
pdgfar
also
use
valid
enrich
human
adult
preoligodendrocyt
procur
surgic
resect
biopsi
subcort
white
matter
tempor
lobe
obtain
medicationrefractori
epilepsi
patient
enrich
achiev
differenti
adher
armstrong
et
al
magnet
activ
cell
sort
use
antibodi
fetal
cell
sim
et
al
differenti
densiti
separ
use
percol
gradient
miron
et
al
rodent
cultur
antibodi
btubulin
btubiii
neurofila
nf
microtubul
associatedprotein
use
demonstr
lack
neuron
contamin
although
cultur
highli
enrich
marker
neural
stem
cell
guarante
cell
cultur
driven
oligodendrocyt
lineag
addit
number
cell
gener
adult
tissu
usual
million
cell
given
tissu
prepar
greatli
limit
use
transcript
profil
assess
compound
vitro
sim
et
al
assay
use
demonstr
differenti
cell
usual
quantit
express
marker
earlier
stage
resort
imagebas
analysi
increas
process
arbor
primari
cultur
rodent
oligodendrocyt
progenitor
harvest
neonat
anim
wide
use
vitro
model
demyelin
remyelin
cultur
gener
easili
purifi
cell
larg
enough
number
medium
throughput
primari
secondari
screen
primari
screen
might
constitut
ten
thousand
compound
wherea
secondari
screen
could
involv
hundr
compound
rodent
oligodendrocyt
prepar
neonat
gener
cell
target
ident
reproduc
experi
experi
adequ
similar
rodent
human
cell
differenti
myelin
process
rodent
cell
valu
search
drug
treatment
human
diseas
tissu
adult
human
oligodendrocyt
fetal
human
progenitor
deriv
may
difficult
obtain
regular
consist
basi
human
cell
difficult
rodent
cell
acquir
larg
enrich
enough
number
primari
screen
acquisit
cell
adult
epilepsi
tissu
deriv
differ
region
brain
vari
degre
patholog
gener
cell
popul
variabl
puriti
fetal
tissu
may
vari
gestat
stage
contrast
rodent
oligodendrocyt
precursor
human
oligodendrocyt
precursor
easili
driven
vitro
express
mbp
often
kept
cultur
sever
week
nevertheless
number
compound
assess
hundr
human
cell
gener
adequ
number
orthologu
valid
assay
compound
origin
select
primari
rodent
librari
screen
spontan
gener
perman
cell
line
resembl
oligodendrocytetyp
astrocyt
precursor
cultur
neonat
rat
cerebr
cortex
gave
rise
bipotenti
cell
line
grown
pdgf
basic
fibroblast
growth
factor
bfgf
cell
prolifer
remov
growth
factor
lead
differenti
cell
within
h
oligodendrocyt
eventu
stain
posit
mbp
transfer
line
fetal
calf
serum
fc
caus
line
differenti
astrocyt
loui
et
al
spontan
differenti
line
need
kept
basal
level
provid
window
agent
drive
differenti
cell
also
use
assess
agent
induc
interfer
excitotox
cell
death
casacciabonnefil
et
al
brogi
et
al
yoshioka
et
al
immort
oligodendrocyt
cell
line
mice
also
creat
use
assess
agent
drive
differenti
protect
cell
death
jensen
et
al
produc
line
deriv
spinal
cord
larg
tantigen
transgen
mous
activ
cell
stain
minim
galc
stimul
forskolin
dibutyryl
cyclic
amp
dbcamp
oligodendrocyt
marker
increas
plp
mrna
howev
unlik
normal
oligodendrocyt
precursor
cell
demonstr
increas
mbp
mrna
protein
like
due
increas
mbp
repressor
immort
murin
oligodendrocyt
cell
line
repres
differ
stage
differenti
lineag
creat
laboratori
anthoni
campagnoni
n
cell
creat
mous
cerebr
primari
cultur
use
retrovir
vector
contain
temperatur
tag
gene
foster
et
al
among
cell
line
cell
line
repres
least
matur
line
shown
sensit
nitric
oxid
induc
mitochondri
damag
death
line
posit
sulfatid
galc
cnp
mbp
mrna
repres
matur
line
least
sensit
cell
death
mackenziegraham
et
al
cell
line
faith
replic
effect
free
radic
seen
use
normal
primari
rodent
oligodendrocyt
progenitor
merril
scold
casacciabonnefil
human
oligodendroglioma
cell
line
hog
merril
matsushima
kashima
et
al
also
evalu
potenti
use
substitut
difficult
obtain
human
oligodendrocyt
precursor
tumor
rare
gener
mix
cell
type
two
line
confirm
oligodendroglioma
immatur
oligodendrocyt
phenotyp
molecular
profil
cell
express
cnp
mrna
protein
mbprelat
mrna
kashima
et
al
cell
behav
like
primari
oligodendrocyt
assay
prolifer
respons
interleukin
benvenist
merril
otero
merril
although
transform
line
may
use
human
oligodendrocyt
precursor
surrog
clear
limit
reliabl
indic
normal
cell
function
especi
differenti
conclus
drug
discoveri
greatli
aid
use
cell
line
deriv
spontan
transform
cell
genet
immort
line
tumor
line
costand
timeeffect
product
use
clonal
unlimit
suppli
uniform
respons
similar
function
exist
normal
cell
made
practic
substitut
primari
screen
entail
five
hundr
thousand
one
million
compound
mix
glial
neuron
cultur
produc
myelin
axon
establish
embryon
day
mous
rat
fetal
telencephalon
mechan
dissoci
siev
placement
chemic
defin
medium
cell
either
allow
attach
grow
mix
stationari
cultur
lubetzki
et
al
demeren
et
al
kept
constant
rotat
within
day
form
aggreg
glia
neuron
tosic
et
al
copelman
et
al
bottensteinsato
medium
supplement
pdgf
aa
embryon
murinemix
stationari
cultur
give
rise
myelin
axon
within
week
time
differenti
oligodendrocyt
determin
galc
mbp
stain
format
compact
myelin
vitro
roughli
vivo
first
myelin
oligodendrocyt
mous
optic
nerv
appear
postnat
day
lubetzki
et
al
demeren
et
al
rotat
cell
suspens
cultur
embryon
rat
dissoci
cell
form
mix
aggreg
within
day
matur
full
axon
myelin
time
scale
similar
myelin
occur
vivo
honnegg
loughlin
et
al
yet
differ
mix
cultur
system
murray
duboisdalcq
report
oligodendrocyt
progenitor
gener
tissu
deriv
day
concept
model
week
vitro
bottensteinsato
medium
divid
neural
stem
cell
cluster
detach
cultur
dish
surfac
continu
expand
sphere
sphere
contain
mostli
multipotenti
polysial
neural
cell
adhes
molecul
psancam
nestin
mitot
neural
precursor
passag
everi
week
gener
new
sphere
month
sphere
frozen
dmso
withdraw
mitogen
permit
develop
cell
differenti
express
galc
myelin
cultur
also
produc
mix
togeth
purifi
popul
neuron
oligodendrocyt
progenitor
separ
prepar
sourc
neuron
usual
murin
dorsal
root
ganglia
drg
neuron
isol
e
wherea
oligodendrocyt
progenitor
may
deriv
mous
rat
postnat
day
cerebr
cortic
mccarthi
develli
drg
cultur
expos
fluorodeoxyuridin
fudr
inhibit
mitos
nonneuron
cell
day
cultur
week
addit
enrich
oligodendrocyt
progenitor
steven
et
al
zhang
et
al
ishibashi
et
al
oligodendrocyt
precursor
differenti
within
week
myelin
within
week
condit
unlik
embryon
mix
cultur
oligodendrocyteneuron
cultur
contain
glia
endotheli
cell
might
modul
myelinaxon
interact
well
influenc
effect
exogen
agent
drug
ad
cultur
promot
cell
surviv
differenti
cerebellar
organotyp
slice
cultur
also
use
examin
effect
agent
myelin
sagitt
slice
mm
neonat
rat
cerebella
prepar
use
tissu
chopper
slice
treat
drug
agent
h
follow
mechan
dissoci
singl
cell
analysi
cell
differenti
steven
et
al
conclus
mix
glial
cultur
complic
singlecel
cultur
establish
use
serv
intermedi
cultur
system
examin
demyelin
remyelin
agent
simpler
singlecel
prepar
resourceconsum
vivo
model
mix
aggreg
sphere
oligodendrocyt
precursor
small
fraction
total
cell
number
also
use
demonstr
capac
hormon
possibl
small
molecul
drive
oligodendrocyt
differenti
although
cultur
techniqu
organotyp
slice
allow
preserv
architectur
nervou
system
stimul
complex
electr
biochem
pathway
may
reproduc
singlecel
mixedcel
cultur
low
throughput
assay
system
evid
myelin
damag
oligodendrocyt
cell
death
occur
ms
lesion
result
excitotox
yoshioka
et
al
lack
inappropri
growth
factor
signal
scold
compston
immun
cellmedi
mechan
selmaj
et
al
selmaj
et
al
proinflammatori
cytokin
brogi
et
al
vartanian
et
al
casacciabonnefil
ceramid
larocca
et
al
casacciabonnefil
et
al
enzym
jame
et
al
free
radic
mitrov
et
al
husain
juurlink
antimog
antibodi
plu
complement
copelman
et
al
form
cell
cytotox
recreat
vitro
assay
quantit
endpoint
oligodendrocyt
differenti
vitro
use
rodent
oligodendrocyt
precursor
accomplish
within
day
vitro
transcript
profil
myelin
differentiationrel
gene
mbp
plp
mag
mog
use
northern
blot
situ
hybrid
perform
minim
number
compound
wherea
rtpcr
high
throughput
genom
technolog
arraypl
htg
inc
tucson
az
microfluid
card
tlda
appli
biosystem
foster
citi
ca
would
use
higher
throughput
blanchard
friend
martel
et
al
analysi
myelin
protein
microscopebas
imag
system
quantit
antibodi
fluoresc
use
twocolor
detect
licor
system
odyssey
infrar
imag
system
licor
lincoln
ne
immunohistochem
elisabas
analys
avail
autom
morphometr
analys
imagebas
highcont
screen
hc
base
determin
shape
cell
distinguish
increas
branch
quantit
secondari
tertiari
process
number
length
use
reagent
like
cellmask
cytoplasmicnuclear
stain
invitrogen
carlsbad
ca
hc
algorithm
compat
autom
digit
cell
microimag
data
acquisit
system
count
softwar
use
analysi
singl
cellom
arrayscan
cellom
pittsburgh
pa
fisher
bioscienc
fisher
lafayett
co
multipl
imag
channel
incel
develop
toolkit
gener
electr
incel
ge
piscataway
nj
hardwar
softwar
system
remov
subject
timeconsum
compon
visual
manual
evalu
differenti
human
oligodendrocyt
precursor
vitro
pose
sever
distinct
differ
cultur
rodent
cell
although
human
precursor
driven
differenti
morpholog
within
day
vitro
mani
case
substanti
number
cell
express
mbp
develop
vitro
week
later
wilson
et
al
thu
feasibl
use
assay
differenti
human
precursor
challeng
rodent
cell
typic
involv
evalu
transit
bipolar
cell
cnp
cell
intermedi
highcomplex
branch
process
zhang
et
al
clear
myelin
regul
physic
contact
matur
oligodendrocyt
axon
product
compact
myelin
occur
axon
function
target
inhibit
abnorm
express
axonassoci
molecul
block
myelin
may
one
way
allow
myelin
proceed
examin
complex
cultur
demeren
et
al
demonstr
mix
stationari
cultur
myelin
could
block
tetrodotoxin
enhanc
ascorpion
toxin
stimul
electr
activ
effect
confirm
vivo
use
develop
optic
nerv
mous
electr
activ
regul
express
cell
adhes
molecul
axon
psancam
axon
coman
et
al
ms
psancam
found
demyelin
axon
chronic
lesion
myelin
axon
myelin
deposit
occur
axon
downregul
psancam
intern
psancam
antibodi
enzymat
remov
polysial
acid
moieti
endoneuraminidas
increas
myelin
fivefold
mix
cultur
charl
et
al
electr
stimul
mix
cocultur
stimul
atp
product
induc
astrocyt
cultur
produc
leukemia
inhibitori
factor
lif
ishibashi
et
al
strong
neurotroph
factor
turn
stimul
myelin
product
matur
oligodendrocyt
cultur
mix
cocultur
vitro
demonstr
oligodendrocyt
progenitor
express
function
adenosin
receptor
detect
action
potenti
axon
larg
intracellular
calcium
flux
adenosin
atp
inhibit
oligodendrocyt
progenitor
prolifer
promot
interact
axon
drive
myelin
cours
day
vitro
steven
et
al
myelin
cultur
system
quantit
count
mbpstain
cell
number
internodesmyelin
segment
toluidin
blue
stain
wilson
valid
compact
myelin
use
em
charl
et
al
demeren
et
al
steven
et
al
exposur
isol
precursor
differenti
oligodendrocyt
agent
promot
prolifer
migrat
surviv
differenti
simplifi
interpret
function
outcom
provid
quantifi
direct
effect
oligodendrocyt
target
uninfluenc
cell
solubl
product
phenotyp
screen
small
molecul
librari
sax
et
al
desir
function
outcom
like
surviv
differenti
analyz
gene
biomark
indic
mechan
drug
action
use
affymetrix
array
microfluid
card
highthroughput
genom
htg
transcript
profil
relev
gene
cluster
sim
et
al
model
allow
vitro
proof
concept
assess
whether
small
molecul
penetr
cell
membran
examin
efficaci
biolog
antibodi
cytokin
neurotroph
factor
import
part
screen
process
agent
may
yet
physic
pharmacokinet
properti
would
allow
reach
pharmacodynam
exposur
level
cross
intact
bloodbrain
barrier
bbb
vivo
mix
cultur
system
technic
challeng
time
consum
allow
assess
pharmacolog
paramet
use
valid
inhibitor
molecul
well
abil
dissect
mechan
action
drug
control
easili
manipul
condit
achiev
vivo
cytokin
neurotroph
factor
among
cytokin
neurotroph
factor
posit
affect
oligodendrocyt
precursor
prolifer
precursor
matur
oligodendrocyt
surviv
matur
differenti
pdgf
bfgf
lif
neurotrophin
glial
growth
neuregulin
insulinlik
growth
ciliari
neurotroph
factor
cntf
beststudi
protein
marmur
et
al
copelman
et
al
sperber
mcmorri
agent
prove
quit
use
posit
control
assay
search
uniqu
small
molecul
perform
similar
function
cell
sourc
import
factor
evalu
mechan
compar
human
cell
fetal
spinal
cord
cell
adult
human
epilepsi
tempor
lobe
report
fetal
cell
prolifer
respons
pdgf
wherea
adult
cell
howev
drive
differenti
fetal
adult
precursor
armstrong
et
al
wilson
et
al
report
basic
fgf
effect
prolifer
either
fetal
adult
human
cell
vitro
wherea
drive
cell
divis
cultur
rodent
precursor
eccleston
silberberg
armstrong
et
al
grinspan
et
al
marmur
et
al
wilson
et
al
depend
stimulu
use
prolifer
assay
progenitor
cell
establish
run
overnight
assay
beyond
day
vitro
assess
use
hthymidin
uptak
ad
last
h
cultur
bromodeoxyuridin
brdu
stain
cyquant
nf
prolifer
assay
kit
invitrogen
autoradiographi
otero
merril
wilson
et
al
grinspan
et
al
armstrong
et
al
quantit
readout
like
radioisotop
incorpor
achiev
small
format
cell
number
limit
human
cell
cultur
cellspecif
antigen
stain
cell
manual
count
zhang
et
al
hormon
estrogen
triiodothyronin
use
tool
vitro
vivo
assess
surviv
differenti
oligodendrocyt
progenitor
estrogen
receptora
b
era
erb
detect
primari
neonat
rat
mous
oligodendrocyt
precursor
vitro
vivo
doubl
stain
immatur
matur
mbp
cell
era
erbspecif
antibodi
demonstr
subcellular
local
nucleu
cytoplasm
confoc
microscopi
nuclear
compartment
becam
pronounc
cell
matur
takao
et
al
although
effect
cell
prolifer
drive
increas
process
day
vitro
nm
zhang
et
al
also
protect
immatur
matur
primari
cell
cytotox
nm
protect
mechan
requir
h
pretreat
confirm
ldh
mtt
readout
block
ici
inhibitor
block
era
erb
receptor
takao
et
al
exposur
time
h
h
primari
cell
thu
make
assay
conveni
one
function
assess
test
anim
model
assess
effect
aggreg
neural
sphere
less
straightforward
still
achiev
requir
week
exposur
hormon
assay
demonstr
myelinspecif
transcript
protein
immunohistochemistri
cell
surfac
marker
matur
oligodendrocyt
morphometri
confirm
matur
oligodendrocyt
mix
cultur
murray
duboisdalcq
tosic
et
al
small
molecul
small
molecul
use
standard
tool
reproduc
gener
cost
less
biolog
camp
analogu
shown
oligoprotect
drive
differenti
dbcamp
mm
increas
number
oligodendrocyt
express
myelin
compon
vitro
week
raibl
mcmorri
campelev
agent
like
mm
forskolin
mm
dbcamp
pdeiv
antagonist
propentofyllin
mm
ibudilast
mm
prevent
kainateinduc
ldh
releas
oligodendrocyt
cultur
recent
small
molecul
current
clinic
trial
treatment
ms
investig
effect
surviv
differenti
oligodendrocyt
vitro
lipophil
analogu
cross
bbb
current
phase
iii
clinic
trial
ms
antiinflammatori
agent
kappo
et
al
agonist
four
g
proteincoupl
receptor
member
endotheli
differenti
generel
edg
famili
davi
et
al
mandala
et
al
differ
time
dosedepend
effect
report
rodent
progenitor
matur
oligodendrocyt
vitro
includ
process
retract
cell
surviv
jaillard
et
al
effect
seen
human
progenitor
expos
vitro
report
miron
et
al
progenitor
surviv
follow
growth
factor
remov
cultur
exposur
nm
nevertheless
previou
studi
show
could
rescu
rodent
preoligodendrocyt
growth
factor
withdrawalinduc
death
suggest
differ
either
rel
receptor
level
subtyp
associ
signal
cascad
human
rodent
toman
et
al
tabl
summar
benefit
liabil
vitro
model
assay
drug
discoveri
model
surviv
repair
abbrevi
na
inform
avail
optic
nerv
oligo
oligodendrocyt
thyroid
hormon
number
mo
month
primari
screen
perform
human
cell
critic
rodent
oligodendrocyt
vitro
assay
secondari
tertiari
screen
essenti
establish
efficaci
vitro
rodent
cell
compound
ultim
evalu
vivo
anim
model
demyelin
remyelin
primari
screen
perform
rodent
cell
cell
line
equal
critic
given
possibl
speci
specif
drug
vitro
assess
posit
effect
develop
candid
drug
human
cultur
addit
limit
use
vitro
rodent
surrog
cell
screen
drug
ultim
use
patient
choic
human
cell
drug
screen
vitro
may
influenc
test
outcom
caveat
kept
mind
respect
expect
compoundmedi
effect
human
clinic
trial
proinflammatori
cytokin
although
mani
studi
use
matur
rodent
oligodendrocyt
progenitor
mix
rodent
cultur
examin
mechan
cell
death
studi
use
human
cell
merril
scold
casacciabonnefil
review
wide
array
vitro
paradigm
show
mechan
pathway
cell
death
vari
consider
one
strike
exampl
ngf
activ
lowaffin
receptor
ngfr
absenc
function
trka
lead
cell
death
matur
oligodendrocyt
cell
ratio
trk
greater
apoptosi
occur
proinflammatori
cytokin
like
ifng
tnfa
induc
ceramid
product
oligodendrocyt
lead
either
apoptot
necrot
cell
death
chakraborti
et
al
casacciabonnefil
et
al
brogi
et
al
ceramid
ceramid
sphingolipid
gener
neutral
acid
sphingomyelinas
action
sphingomyelin
second
messeng
capabl
mediat
oligodendrocyt
cell
death
apoptot
death
occur
consequ
ceramid
elev
cjun
cjun
aminotermin
kinas
jnk
activ
casacciabonnefil
agent
use
direct
toxin
vitro
kill
oligodendrocyt
primari
oligodendrocyt
precursor
matur
oligodendrocyt
behav
similarli
undifferenti
differenti
cell
respect
respons
ceramid
ceramid
maxim
cell
death
achiev
mm
primari
progenitor
sensit
ceramid
matur
primari
oligodendrocyt
cell
appear
sensit
primari
cell
assay
cell
assay
time
h
suffici
achiev
greater
cell
death
primari
cell
gener
need
expos
toxin
h
especi
lower
dose
astrocyt
neuron
resist
form
cell
death
cellbas
readout
assay
includ
livedead
cell
assay
molecular
probe
eugen
apoptosi
detect
kit
apoptag
plu
oncor
gaithersburg
md
mtt
mitochondri
enzym
function
assay
use
tetrazolium
bromid
boehring
mannheim
germani
excitotox
excitotox
attribut
ischemia
inflamm
implic
oligodendrocyt
deplet
within
ms
lesion
rain
prinea
prinea
et
al
prinea
et
al
cell
oligodendrocyt
lineag
express
kainat
ampa
type
nonnmethyldaspart
acid
glutam
receptor
patneau
et
al
yoshioka
et
al
prolong
activ
receptor
lead
increas
intracellular
calcium
ca
increas
inositol
phosphat
earli
gene
induct
inhibit
prolifer
migrat
precursor
gallo
et
al
wang
et
al
knutson
et
al
matur
oligodendrocyt
death
also
shown
occur
model
vitro
use
cell
differenti
cell
cultur
h
presenc
mm
kainat
cell
death
quantit
measur
activ
lactat
dehydrogenas
ldh
yoshioka
et
al
free
radic
human
glial
cell
macrophag
capabl
make
vitro
vivo
increas
induc
synthas
ino
respons
pathologyinduc
level
detect
ms
tissu
rtpcr
bo
et
al
enzym
activ
produc
evidenc
nadph
diaphoras
stain
astrocyt
edg
chronic
lesion
brosnan
et
al
increas
level
nitrit
nitrat
ms
cerebrospin
fluid
csf
johnson
et
al
nitrotyrosin
nt
stain
ms
tissu
indic
peroxynitrit
format
chemic
reaction
superoxid
anion
addit
evid
lipid
peroxid
occur
ms
tissu
put
forth
refer
prinea
et
al
prinea
et
al
hunter
et
al
rain
wu
oligodendrocyt
precursor
easili
damag
free
radic
nitrogen
oxygen
less
matur
cell
sensit
myelinproduc
cell
oligodendrocyt
sensit
effect
free
radic
microglia
astrocyt
husain
juurlink
cell
death
appear
mainli
necrot
ms
lesion
vitro
cultur
hallmark
process
withdraw
singlestrand
dna
break
swollen
nuclei
cytoplasm
organel
disrupt
plasma
membran
damag
mitochondri
dysfunct
prinea
et
al
prinea
et
al
mitrov
et
al
mitrov
et
al
thorburn
juurlink
report
compar
astrocyt
oligodendrocyt
iron
lower
level
manganes
superoxid
dismutas
half
amount
reduc
glutathion
less
level
glutathion
peroxidas
thu
consequ
abl
scaveng
harm
radic
oligodendrocyt
much
vulner
free
radicalmedi
death
detail
vitro
assay
system
model
free
radicalmedi
cell
damag
death
describ
detail
elsewher
mitrov
et
al
mix
cultur
set
assess
effect
anoxia
vari
degre
hypoxia
purg
close
incub
chamber
differ
ratio
n
co
lipid
peroxid
assess
use
cytochem
procedur
demonstr
thiobarbitur
acid
fluoresc
adduct
conjunct
morpholog
evalu
cell
death
abil
detect
cellular
free
radic
scaveng
achiev
use
dichlorohydrofluorescein
intracellular
probe
oxid
stress
husain
juurlink
simpler
higher
throughput
cytotox
vitro
system
use
purifi
oligodendrocyt
progenitor
matur
oligodendrocyt
microglia
neuron
astrocyt
use
chemic
donor
free
radic
nitrogen
oxygen
gener
snitrosonacetyldlpenicillamin
snap
wherea
pyrogallol
gener
superoxid
anion
gener
quickli
react
gener
peroxynitrit
onoo
achiev
use
peroxynitrit
also
gener
mix
equal
mole
pyrogallol
snap
snap
caus
signific
mitochondri
enzym
damag
oligodendrocyt
mm
less
cell
death
even
mm
pyrogallol
caus
signific
cell
death
mm
death
mitochondri
damag
mm
h
vitro
mitrov
et
al
oxyhemoglobin
gener
use
posit
control
inhibit
snapinduc
mitochondri
damag
quantit
multiplex
assay
cell
death
includ
releas
incorpor
label
protein
cr
hleucin
nucleotid
hthymidin
releas
ldh
uptak
propidium
iodid
trypan
blue
vital
dye
cell
type
like
astrocyt
damag
without
die
expos
free
radic
cell
damag
detect
use
assay
activ
ferrosulfurcontain
enzym
succin
dehydrogenas
nonradioact
proliferationcytotox
kit
cytotox
fluor
assay
promega
madison
wi
assay
base
abil
intact
enzym
cleav
mtt
tetrazolium
salt
blue
product
formazan
isocitr
dehydrogenas
nonferrosulfur
contain
enzym
use
control
assay
valid
mechan
cell
death
techniqu
use
em
dnaladd
gel
differenti
alkalin
precipit
dna
determin
proport
dna
strand
singlestrand
fraction
total
cellular
dna
employ
mitrov
et
al
lieu
use
cocultur
cell
macrophagesmicroglia
oligodendrocyt
target
proinflammatori
mediat
gener
effector
cell
may
ad
directli
matur
oligodendrocyt
precursor
highthroughput
assay
viabil
end
point
avail
determin
mechan
cell
death
achiev
direct
laborintens
assay
electron
microscopi
em
mix
cultur
use
antibodi
specif
cell
type
cuprizon
young
adult
male
mice
week
old
suscept
demyelin
produc
diet
cuprizon
biscyclohexanon
oxaldihydrazon
ludwin
demyelin
occur
global
throughout
white
matter
easili
detect
within
corpu
callosum
demyelin
evid
within
week
start
cuprizon
diet
complet
week
replac
diet
normal
food
allow
almost
complet
remyelin
within
week
matsushima
morel
adamo
et
al
produc
similar
model
demyelin
wistar
rat
cuprizon
week
remyelin
occur
significantli
week
normal
diet
immunohistochem
stain
axon
damag
use
amyloid
precursor
protein
app
bielschowski
silver
impregn
reveal
much
axon
damag
mice
though
axon
transect
increas
significantli
age
mice
therebi
greatli
impair
repair
irvin
blakemor
microglia
macrophag
requir
effici
remyelin
gilson
blakemor
quantit
tissu
section
stain
marker
biotininconjug
ricinu
communi
sigma
madison
wi
matur
oligodendrocyt
number
quantit
stain
antibodi
antiadenomat
polyposi
coli
calbiochem
san
diego
ca
adamo
et
al
antibodi
pisoform
glutathionestransferas
gstp
gstp
stain
immatur
oligodendrocyt
mason
et
al
mason
et
al
medium
throughput
assay
myelin
loss
achiev
harvest
entir
brain
run
quantit
mbp
protein
dot
blot
altern
timeconsum
identif
actual
tissu
myelin
loss
repair
involv
quantit
stereolog
use
comput
assist
stereolog
toolbox
cast
system
cast
grid
olympu
center
valley
pa
assess
myelin
corpu
callosum
use
follow
lfb
stain
toluidin
blue
em
necessari
final
step
assur
compact
myelin
invest
nake
axon
avail
ideal
abl
appli
measur
anim
model
might
use
clinic
merkler
et
al
recent
demonstr
produc
accur
magnet
reson
imag
mri
predict
statu
myelin
corpu
callosum
cuprizonef
mice
use
combin
weight
weight
magnet
transfer
ratio
mtr
valu
bruker
billerica
biospin
small
anim
mri
francopon
et
al
describ
use
open
field
rotorod
test
cuprizon
model
claim
function
deficit
cuprizonef
mice
compar
normal
fed
control
whether
either
translat
assay
prove
sensit
enough
detect
drug
effect
anim
model
remain
determin
ethidium
bromid
solut
ethidium
bromid
etbr
stereotact
inject
follow
surgic
prepar
thoracolumbar
dorsal
funiculu
spinal
cord
caudal
cerebellar
peduncl
ccp
etbr
also
inject
subarachnoid
space
therebi
caus
demyelin
optic
nerv
chiasm
spraguedawley
wistar
rat
week
old
etbr
demyelin
begin
within
h
may
complet
week
depend
concentr
etbr
cuprizon
model
macrophag
andor
microgli
cell
remov
myelin
debri
essenti
repair
graca
blakemor
guazzo
demyelin
extens
contain
within
circumscrib
area
ccp
minim
volum
inject
lesion
size
also
etbr
concentrationdepend
etbr
injur
nucleat
cell
type
mechan
action
dnaintercol
agent
astrocyt
damag
within
etbr
lesion
area
schwann
cell
abl
migrat
remyelin
oligodendrocyt
repopul
area
woodruff
franklin
sim
et
al
spontan
remyelin
occur
outsid
lesion
inward
toward
center
extens
month
follow
lesion
product
axon
spare
signific
proport
nake
axon
remain
demyelin
ccp
week
etbr
inject
anim
age
month
spontan
remyelin
model
less
effici
ibanez
et
al
sim
et
al
assign
repair
exogen
stem
cell
transplant
therapi
model
modifi
local
highdos
irradi
gy
xray
etbr
franklin
blakemor
blakemor
franklin
evalu
oligodendrocyt
precursor
intact
myelin
accomplish
use
assay
similar
previous
describ
requir
tediou
dissect
lesion
area
elimin
background
nois
normal
surround
area
honmou
et
al
abl
demonstr
conduct
block
quantit
compound
action
potenti
spinal
cord
anim
subject
etbr
lesion
function
repair
transplant
schwann
cell
revers
slow
conduct
veloc
assess
ex
vivo
use
field
potenti
intraaxon
record
segment
spinal
cord
involv
lesion
lysolecithin
lysophosphatidylcholin
sigma
detergentlik
membran
solubil
agent
inject
follow
surgic
prepar
brain
spinal
cord
stereotax
posit
hamilton
syring
solut
agent
creat
demyelin
lesion
adult
mice
rat
administ
dorsal
funiculu
spinal
cord
ccp
gregg
et
al
girard
et
al
right
centrum
semioval
craniometri
adult
male
macaqu
monkey
dousset
et
al
mice
young
adult
rat
myelin
debri
complet
remov
remyelin
begun
day
lesion
spinal
cord
total
remyelin
albeit
thin
myelin
sheath
seen
month
jeffrey
blakemor
kotter
et
al
old
male
rat
day
old
center
lesion
remain
complet
demyelin
month
gilson
blakemor
macrophag
deplet
demyelin
model
impair
remyelin
kotter
et
al
rat
ccp
lesion
remyelin
proceed
slower
spinal
cord
patch
oligodendrocyt
progenitor
obviou
lesion
edg
week
remyelin
ccp
evid
week
axon
appear
compact
myelin
week
use
em
woodruff
franklin
monkey
rodent
maximum
myelin
loss
seen
histolog
magnet
transfer
ratio
mtr
day
dousset
et
al
astrocyt
axon
spare
demyelin
model
oligodendrocyt
primari
remyelin
cell
faster
remyelin
may
occur
oligodendrocyt
progenitor
spare
greater
extent
model
etbr
model
woodruff
franklin
etbr
model
target
lesion
area
must
dissect
analysi
see
tabl
comparison
chemic
induc
demyelin
model
sever
type
anim
model
produc
demyelin
serv
use
inlif
pharmacolog
tool
assess
compound
chemic
induc
cn
lesion
gener
cuprizon
feed
inject
etbr
lysolecithin
sever
distinct
advantag
dissoci
demyelin
event
complex
introduc
tissu
patholog
chronic
inflammatori
cell
solubl
mediat
reproduc
time
spontan
remyelin
robust
deremyelin
anatom
distinct
area
facilit
focus
quantit
assess
lesion
gener
repair
graca
blakemor
jeffrey
blakemor
honmou
et
al
woodruff
franklin
matsushima
morel
mason
et
al
mason
et
al
ibanez
et
al
girard
et
al
guazzo
eae
mice
experiment
autoimmun
encephalomyel
eae
autoimmun
model
produc
activ
immun
rat
mice
marmoset
use
whole
brain
spinal
cord
homogen
sch
purifi
myelin
protein
plp
mog
mbp
adopt
transfer
use
activ
myelin
antigenspecif
cell
genain
hauser
tiwariwoodruff
et
al
pluchino
et
al
dalal
et
al
rain
et
al
wuerfel
et
al
beeton
et
al
analysi
inbr
mous
strain
demonstr
specif
major
histocompat
haplotyp
mhc
confer
suscept
diseas
gender
antigen
specif
activ
subcutan
immun
femal
sjlj
mice
plp
peptid
emulsifi
complet
freund
adjuv
cfa
supplement
mycobacterium
tuberculosi
two
inject
pertussi
toxin
day
apart
produc
relapsingremit
diseas
similar
ms
diseas
evid
day
peak
end
second
week
first
attack
patholog
first
attack
strictli
inflammatori
follow
remiss
subsequ
attack
includ
inflamm
demyelin
axon
loss
cell
dendrit
cell
macrophag
endogen
glia
involv
diseas
butzkueven
et
al
contrast
rmog
hmog
induc
chronic
eae
femal
mice
inflamm
demyelin
oligodendrocyt
neuron
death
axon
loss
occur
within
first
week
diseas
human
mog
induc
demyelin
primarili
antibodi
mediat
thu
produc
patholog
similar
seen
ms
lesion
tabl
tiwari
woodruff
et
al
kanwar
et
al
laliv
et
al
bernard
arnon
offner
two
model
complementari
util
drug
discoveri
tempor
separ
patholog
inflamm
vs
tissu
damag
relapsingremit
natur
diseas
plp
model
allow
assess
antiinflammatori
prorepair
drug
well
comparison
prophylact
therapeut
intervent
chronic
model
allow
specif
assess
agent
target
b
cell
hmog
model
demonstr
axon
damag
cell
death
earlier
time
point
seen
plp
model
therebi
shorten
inlif
dose
compat
creation
knock
transgen
mice
target
drug
valid
eae
rat
even
though
rat
model
consum
drug
substanc
mous
model
rat
eae
model
may
necessari
proof
concept
assess
due
select
andor
pharmacokinet
pharmacodynam
drug
test
addit
assess
drug
effect
use
mri
electrophysiolog
may
made
easili
use
rat
bechtold
et
al
brochet
et
al
acut
nonrelaps
eae
activ
induc
lewi
rat
use
guinea
pig
sch
mbp
cfa
tuberculosi
flori
et
al
berger
et
al
increas
concentr
encephalitogen
antigen
andor
tuberculosi
diseas
phase
prolong
induct
relaps
pattern
achiev
strain
rat
feurer
et
al
acut
monophas
model
lewi
rat
demonstr
neurolog
deficit
day
peak
day
resolv
day
time
anim
resist
reinduct
diseas
model
one
rel
short
durat
advantag
demyelin
cell
death
axon
loss
use
limit
assess
antiinflammatori
drug
rat
mog
induc
chronic
nonrelaps
eae
femal
brown
norway
rat
given
cfa
tuberculosi
mi
et
al
diem
et
al
dose
mog
given
femal
dark
agouti
da
rat
whole
homolog
rat
sch
given
male
da
rat
without
tuberculosi
anim
develop
relapsingremit
diseas
issazadeh
et
al
lorentzen
et
al
brochet
et
al
fernandez
et
al
figur
relapsingremit
model
sjlj
mice
peak
diseas
da
rat
achiev
end
second
week
follow
remiss
strictli
inflammatori
natur
anim
experi
diseas
first
remiss
rel
synchron
manner
subsequ
attack
asynchron
among
anim
involv
demyelin
involv
macrophag
antimyelin
antibodi
well
axon
loss
lorentzen
et
al
issazadeh
et
al
inflamm
verifi
model
rtpcr
stain
proinflammatori
marker
cell
product
rat
eae
model
recent
shown
macrophag
track
vivo
weight
mri
imag
cell
label
ultra
small
particl
iron
oxid
uspio
sinarem
guerbet
pari
franc
particl
phagocytos
macrophag
peripheri
da
rat
eae
model
cell
migrat
first
cervic
cord
subsequ
brain
stem
cerebellum
diseas
progress
detect
hypointens
imag
halflif
hour
uspio
inject
repeatedli
anim
longitudin
studi
map
time
locat
inflammatori
cell
intact
anim
therebi
accomplish
addit
contrast
agent
gadolinium
diethylenetriaminepentaacet
gddpta
magnevist
schere
berlin
germani
gadofluorin
schere
use
mri
imag
discern
leakag
bbb
correl
made
regard
bbb
breakdown
inflammatori
cell
invas
cn
brochet
et
al
berger
et
al
similar
studi
report
murin
adopt
transfer
model
eae
smorodchenko
et
al
anderson
et
al
mbp
exon
transcript
normal
express
extrem
low
level
adult
cn
elev
remyelin
detect
tissu
use
situ
hybrid
ish
immunohistochemistri
jordan
et
al
kanwar
et
al
model
myelin
axon
damag
loss
identifi
describ
chemic
induc
lesion
use
myelin
histolog
toluidin
blue
lfb
immunostain
nf
app
em
lysolecithinmedi
demyelin
model
mri
magnet
transfer
ratio
mtr
use
measur
myelin
loss
eae
model
diffus
tensor
imag
dti
take
advantag
anisotrop
natur
water
diffus
tissu
allow
detail
review
microstructur
inform
use
confirm
axon
integr
mtr
dti
techniqu
use
rat
marmoset
eae
model
mi
et
al
berger
et
al
fujiyoshi
et
al
brok
et
al
thu
small
anim
mri
magnet
philip
best
netherland
bruker
horizont
bore
nmr
spectromet
varian
palo
alto
ca
becom
readili
avail
standardli
use
chronic
inlif
monitor
patholog
eae
model
demyelin
model
sever
model
spinal
cord
injuri
focal
ischemia
lead
demyelin
partial
spare
axon
produc
rodent
monkey
spinal
cord
lesion
creat
weight
drop
contus
hemisect
ischem
insult
produc
min
middl
cerebr
occlus
mcao
although
model
fulli
explor
chapter
mention
induc
endogen
repair
respons
lend
quantit
biochem
histolog
mri
analys
drug
intervent
stem
cell
therapi
seen
eae
model
tanaka
et
al
ohori
et
al
fujiyoshi
et
al
yang
et
al
locat
inject
length
time
infus
properti
toxic
agent
defin
whether
damag
limit
revers
restrict
oligodendrocyt
without
longterm
macroscop
alter
lead
shortterm
direct
attack
myelin
result
longterm
damag
myelin
indirectli
due
oligodendrocyt
loss
inject
peroxynitrit
donor
white
matter
corpu
callosum
rat
lead
sever
myelin
alter
within
day
start
vacuol
myelin
membran
consequ
snitrosyl
protein
includ
plp
boullern
benjamin
brief
infus
kainat
caus
oligodendrocyt
apoptosi
infus
last
sever
day
produc
massiv
oligodendrocyt
progenitor
cell
death
demyelin
plaqu
axon
damag
inflamm
matut
et
al
singl
dose
gy
irradi
rodent
cervic
spinal
cord
produc
apoptot
oligodendrocyt
h
demyelin
week
later
atkinson
et
al
inject
kainat
antigalactocerebrosid
antig
c
may
made
optic
nerv
dorsal
spinal
cord
ccp
therebi
focus
lesion
format
facilit
subsequ
analysi
damag
repair
sergott
et
al
woodruff
franklin
barr
et
al
although
publish
studi
employ
antig
c
use
convent
polyclon
antibodi
serum
rabbit
combin
guinea
pig
complement
barr
et
al
implant
mous
hybridoma
cell
line
secret
antig
c
rat
optic
nerv
inject
antibodi
complement
adult
rat
lumbar
cord
show
demyelin
day
remyelin
commenc
day
complet
remyelin
day
keirstead
et
al
sergott
et
al
inject
antibodi
complement
guinea
pig
optic
nerv
demonstr
myelin
vesicul
day
nake
axon
day
remyelin
begin
day
inject
antibodi
complement
ccp
produc
greatest
delay
demyelin
repair
demyelin
seen
week
remyelin
oligodendrocyt
start
week
inject
extens
remyelin
within
ccp
appar
week
took
month
repair
complet
woodruff
franklin
comparison
demyelin
model
summar
tabl
bypass
induct
global
inflamm
altern
strategi
vivo
demyelin
achiev
administ
agent
directli
damag
oligodendrocyt
precursor
myelin
antigalc
plu
complement
kainit
irradi
theiler
corona
viru
infect
exampl
model
dal
canto
lipton
jordan
et
al
touil
et
al
matut
et
al
atkinson
et
al
boullern
benjamin
gener
use
mous
model
prefer
less
drug
substanc
requir
consider
import
daili
dose
paradigm
chronic
last
sever
week
howev
case
particular
requir
model
gener
analysi
lend
one
speci
anoth
lack
ident
molecular
target
adequ
homolog
target
molecul
speci
rodent
compar
human
speciesspecif
potenc
certain
drug
pharmacokinet
properti
peculiar
given
speci
use
rat
guinea
pig
nonhuman
primat
may
necessari
vivo
drug
screen
eae
model
interest
drug
screen
faith
repres
patholog
seen
ms
use
marmoset
eae
model
take
advantag
potenti
crossreact
monkey
therapeut
agent
well
human
reagent
cell
biomark
identif
addit
mri
electrophysiolog
techniqu
may
employ
model
cognit
visual
acuiti
assess
chronic
safeti
also
conduct
model
provid
advantag
rodent
model
remyelin
achiev
vivo
demyelin
anim
model
use
sever
differ
approach
use
antiinflammatori
drug
may
creat
permiss
environ
endogen
repair
occur
absenc
ongo
diseas
flori
et
al
dalal
et
al
kanwar
et
al
tiwariwoodruff
et
al
mani
publish
studi
demonstr
efficaci
growth
factor
small
molecul
induc
expans
precursor
recruit
site
patholog
drive
differenti
endogen
oligodendrocyt
progenitor
okano
et
al
stangel
franklin
webster
oudega
et
al
lachapel
et
al
adamo
et
al
neuroprotect
drug
hormon
preserv
integr
function
cell
axon
myelin
spite
ongo
patholog
success
use
anim
model
permit
repair
diem
et
al
stangel
butzkueven
et
al
mason
et
al
tiwariwoodruff
et
al
kanwar
et
al
antibodi
neutral
inhibitori
molecul
block
remyelin
also
effect
vivo
mi
et
al
stem
cell
review
depth
chapter
either
replac
precursor
deplet
chronic
demyelin
andor
produc
factor
reduc
glial
scar
inflamm
axon
loss
mason
et
al
pluchino
et
al
small
molecul
chemic
engin
potent
select
solubl
oral
avail
may
prefer
biolog
taken
patient
himherself
pill
may
fewer
side
effect
irrit
inject
site
flulik
symptom
one
molecul
teriflunomid
inhibitor
dihydroorot
dehydrogenas
current
phase
iii
trial
treatment
ms
antiinflammatori
agent
inhibit
tand
bcell
prolifer
function
drug
contend
among
first
oral
avail
drug
treat
diseas
teriflunomid
activ
sever
eae
model
administ
oral
rout
daili
da
rat
reduc
induct
sever
eae
inhibit
demyelin
prevent
axon
loss
increas
conduct
veloc
manuscript
accept
j
neurol
vivo
effect
teriflunomid
provid
exampl
speci
straindepend
differ
seen
differ
eae
model
respect
minim
effect
dose
efficaci
figur
acut
lewi
rat
relapsingremit
da
rat
eae
model
drug
efficaci
minim
effect
dose
mgkg
dose
diseas
virtual
elimin
acut
model
wherea
delay
reduc
sever
relapsingremit
model
figur
plpinduc
sjlj
eae
mous
model
prophylact
dose
mgkg
effect
wherea
mgkg
delay
onset
diseas
although
delay
mice
eventu
get
eae
diseas
sever
vehicl
control
howev
mgkg
teriflunomid
given
prophylact
moginduc
mice
elimin
diseas
induct
figur
teriflunomid
effect
mgkg
given
therapeut
remiss
da
rat
model
given
prophylact
model
figur
therapeut
administr
teriflunomid
relapsingremit
experiment
autoimmun
encephalomyel
eae
model
rat
mice
eae
induc
rat
mice
produc
relapsingremit
diseas
vehicl
control
treat
teriflunomid
eae
dark
agouti
da
rat
induc
spinal
cord
homogen
sch
wv
salin
figur
dex
dexamethason
dose
mgkg
per
day
dose
teriflunomid
day
first
dose
postdiseas
induct
indic
red
arrow
drug
total
ineffect
given
therapeut
diseas
onset
sjlj
mous
model
figur
explan
differ
drug
effect
relapsingremit
model
sjlj
mous
da
rat
may
teriflunomid
less
potent
enzym
bind
inhibit
mous
rat
lower
antiprolif
activ
mous
lymphocyt
rat
lymphocyt
fox
et
al
clearli
differ
explan
differ
drug
effect
two
differ
mous
eae
model
time
cours
patholog
two
mous
eae
model
differ
significantli
see
might
anticip
drug
may
affect
addit
cell
type
b
cell
involv
mog
model
aspect
therapeut
efficaci
current
investig
antibodi
biolog
agent
cross
intact
bbb
deliv
oral
need
inject
anim
model
antibodi
gener
inject
intraperiton
ip
intraven
iv
tail
vein
inject
antiinflammatori
antibodi
act
cell
peripher
blood
prevent
access
function
cn
administ
less
frequent
ie
day
chronic
small
molecul
still
effect
kanwar
et
al
describ
antiinflammatori
antibodi
mucos
addressin
cell
adhes
whose
effect
three
inject
mgkg
iv
sustain
sever
month
monotherapi
effect
antiinflammatori
antibodi
conjunct
peptid
repair
ampakain
receptor
antagonist
f
quinoxalin
nbqx
neuroprotect
even
better
antibodi
alon
studi
repres
exampl
combin
therapi
complimentari
drug
treat
differ
aspect
diseas
might
envis
treatment
ms
howev
cellular
molecular
target
antibodi
treatment
resid
within
cn
bbb
intact
strategi
deliveri
antibodi
site
patholog
requir
antibodi
deliv
intrathec
way
alzet
miniosmot
pump
anim
moginduc
eae
inhibit
key
neg
regul
oligodendrocyt
differenti
myelin
within
week
treatment
eae
diseas
slow
axon
integr
preserv
spinal
cord
remyelin
initi
mi
et
al
neurotroph
factor
protein
difficult
deliv
chronic
exogen
therapeut
agent
anim
model
need
inject
frequent
releas
sustain
fashion
may
short
plasma
halflif
may
induc
neutral
antibodi
render
ineffect
time
investig
appli
innov
strategi
demonstr
posit
role
neurotroph
factor
oligodendrocyt
cell
surviv
demyelin
model
mason
et
al
solv
problem
chronic
deliveri
creat
cuprizon
model
transgen
mice
wherea
barr
et
al
deliv
pdgf
cn
side
bbb
implant
hybridoma
cell
line
secret
neurotroph
factor
oudega
et
al
use
semiperm
polym
tube
contain
matrigel
implant
schwann
cell
bath
pdgf
alzet
mini
pump
implant
sc
ip
case
prolactin
deliveri
drive
remyelin
gregg
et
al
subcutan
sustain
releas
pellet
use
deliveri
estrogen
oligodendrocyt
protect
progesteron
produc
myelin
repair
within
week
testosteron
whose
therapeut
administr
elimin
mbpinduc
eae
sjlj
mice
offner
ibanez
et
al
dalal
et
al
simpler
mode
drug
deliveri
avoid
need
genet
manipul
cell
anim
use
devic
complex
surgic
implant
accommod
sustain
drug
exposur
bbb
penetr
daili
subcutan
inject
success
use
administr
neurotroph
factor
lif
hormon
like
thyroid
hormon
estrogen
eae
butzkueven
et
al
tiwariwoodruff
et
al
fernandez
et
al
document
lif
enter
cn
mediat
surviv
oligodendrocyt
equal
effect
given
ip
ineffect
administ
iv
butzkueven
et
al
estrogen
antiinflammatori
neuroprotect
ovariectom
mice
eae
given
prophylact
estrogen
neuroprotect
effect
evid
day
mog
eae
model
howev
delay
treatment
time
show
estrogen
effect
inde
hormon
work
better
murin
eae
model
start
day
diseas
induct
offner
tiwariwoodruff
et
al
mention
small
molecul
signific
mous
strain
differ
respect
sensit
neuroprotect
effect
estrogen
influenc
choic
model
impact
result
offner
summari
comparison
featur
vivo
model
shown
tabl
vivo
repair
greatli
influenc
anim
model
chosen
proof
concept
model
addit
complex
ad
fact
neurotroph
factor
like
ggf
neuroprotect
agent
promot
remyelin
also
act
antiinflammatori
molecul
lymphocyt
may
produc
neurotroph
factor
tcell
product
bdnf
proinflammatori
cytokin
ifng
tnfa
may
act
prorepair
molecul
review
stangel
routeloc
time
drug
deliveri
chosen
use
variou
model
may
dictat
physic
characterist
drug
target
patholog
affect
eas
difficulti
drug
deliveri
site
action
model
depend
natur
therapi
small
molecul
vs
biolog
agent
vs
transplant
cell
pharmacokinet
exposur
metabol
clearanc
drug
onoff
rate
kinet
bloodbrain
penetr
solubl
among
characterist
illustr
flow
screen
tree
librari
small
molecular
weight
compound
start
primari
screen
proof
concept
poc
model
consid
receptor
whose
activ
necessari
oligodendrocyt
differenti
ultim
remyelin
hypothet
target
primari
screen
could
promoterreport
base
screen
gene
directli
specif
activ
ligand
bind
receptor
screen
could
perform
plate
format
use
half
million
compound
singl
dose
would
requir
cell
follow
valid
assay
system
standard
tool
posit
control
primari
screen
could
conduct
use
stabli
transfect
rodent
oligodendrocyt
cell
line
hit
rate
compound
reconfirm
ic
would
perform
million
cell
orthogon
secondari
screen
usual
perform
hundr
activ
compound
could
carri
cell
primari
oligodendrocyt
might
receptor
bind
assay
assay
would
also
requir
million
cell
tertiari
screen
involv
differenti
primari
rodent
oligodendrocyt
precursor
would
like
involv
ten
hundr
compound
could
perform
format
requir
million
cell
human
orthologu
assay
screen
fewer
compound
perform
use
primari
human
fetal
adultderiv
progenitor
addit
screen
induct
myelin
use
mix
cell
cultur
option
stage
fewer
compound
pursu
acut
vivo
model
assess
abil
molecul
enter
brain
hit
molecular
target
would
perform
next
model
would
fast
turnaround
hour
day
could
biochem
molecular
readout
assess
remyelin
would
perform
remyelin
model
cuprizon
model
would
reserv
lead
compound
develop
candid
chosen
final
assess
compound
abil
drive
remyelin
would
perform
diseas
poc
model
eae
model
choic
develop
drug
treat
ms
futur
hold
promis
use
drug
drive
repair
cn
mri
technolog
mtr
dti
distinguish
quantit
repair
nervou
system
human
becom
refin
standard
incorpor
grow
use
small
anim
mri
assess
drug
drive
remyelin
anim
model
use
routin
human
clinic
trial
peripher
biomark
drugtarget
interact
surrog
peripher
blood
tissu
marker
drug
efficaci
within
cn
may
well
establish
anim
model
ultim
assist
doserang
find
predict
respond
vs
nonrespond
human
trial
drug
mechan
action
better
defin
use
transcript
profil
anim
model
drug
respond
clinic
trial
combin
therapi
drug
drive
repair
preserv
integr
axon
myelin
need
evalu
use
chronic
diseas
like
ms
well
compat
safeti
efficaci
given
antiinflammatori
drug
